Peptides: what they are, what works, and what's hype

Only a handful of peptides have strong human evidence behind them, and the best known are the GLP-1 weight loss medicines. Most of the peptides now trending online — BPC-157, TB-500, growth hormone boosters — rest largely on animal studies and are sold outside regulated channels.

This guide explains what peptides are, how the trending ones compare with approved weight loss medicines, and what the research does and does not show.

What a peptide actually is

A peptide is a short chain of amino acids, the same building blocks that make up proteins. The usual dividing line is about 50 amino acids: shorter chains are called peptides, longer ones proteins.

Your body makes hundreds of them as signalling molecules. Insulin controls blood sugar, oxytocin triggers labour contractions, and GLP-1 tells the brain you are full after eating. More than 80 peptide medicines are approved worldwide.

So “peptide” describes a chemical structure, not a category of safety or effectiveness. Insulin and an unlabelled vial bought online are both peptides. What matters is the evidence behind a specific molecule and how it was made.

GLP-1 medicines: the benchmark

Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro; sold as Zepbound in the US) are peptides, and they set the standard every other peptide should be judged against. Both copy gut hormones that slow stomach emptying and reduce appetite. Tirzepatide also acts on a second hormone, GIP.

Their evidence comes from large, placebo-controlled trials published in peer-reviewed journals, for example:

Beyond weight, semaglutide has shown cardiovascular benefit in people with heart disease. The side effects are well characterised: mostly nausea, vomiting, diarrhoea and constipation, with rarer risks such as gallbladder problems and pancreatitis. Each batch is made under pharmaceutical manufacturing standards and monitored after approval.

That combination of large trials, known risks and controlled manufacturing is what most trending peptides lack.

The trending peptides, ranked by evidence

Only one trending peptide, retatrutide, has a large drugmaker behind it and phase 3 human trials. For the rest, the human evidence ranges from a few small studies to none.

BPC-157, TB-500 and CJC-1295 are banned in sport, and the anti-doping catch-all for unapproved substances can cover the others. That matters for anyone who is tested.

A useful test: if a product’s claims rest on rodent studies, testimonials or a clinic’s own outcomes, it is still experimental, whatever the marketing says.

Where the law stands

In the UK

None of these peptides is licensed in the UK, and there is no UK equivalent of the US compounding route. Selling or supplying an unlicensed medicine is illegal under the Human Medicines Regulations 2012.

• “Research use only” labels are disregarded. The MHRA says it sets these claims aside when marketing shows a product is meant for people, and will act against the seller.
• Retatrutide is not authorised anywhere. In October 2026, the MHRA and West Midlands Police seized more than 12,000 fake retatrutide and tirzepatide pens, worth about £2 million, from a Birmingham unit.
• Genuine GLP-1 medicines come as pre-filled pens or tablets. Powder vials that need mixing are not authorised.

In the US

None of the trending peptides above is FDA-approved, and as of November 2026 none can legally be compounded by US pharmacies. The rules have shifted quickly this year:

1. Late 2023: The FDA placed 19 peptides, including BPC-157, in “Category 2”, meaning pharmacies could not compound them because of safety concerns.
2. April 2026: Twelve, including BPC-157, TB-500, MOTS-c and Semax, were removed from Category 2 after their nominations were withdrawn. Removal did not make them legal to compound.
3. July 2026: An FDA advisory committee narrowly voted to add six peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax — to the list pharmacies may compound from. FDA staff scientists had unanimously opposed every one, citing missing trial data, inconsistent batches and immune-reaction risks.
4. Next: The vote is not binding. The FDA must propose and finalise a rule, which can take up to a year.

Even if these peptides are listed, that would allow pharmacy compounding, not FDA approval. It would not require the trials that semaglutide and tirzepatide went through.

“Research use only” labels do not make a product legal for people. The FDA has sent warning letters to retatrutide sellers and said in June 2026 that selling unapproved versions is illegal. In August 2026, Lilly sued six companies over retatrutide sales.

Why the evidence gap matters

The risk is not only that a peptide might not work. It is that nobody knows what is in the vial, what dose is safe, or what happens over years of use.

• Animal results often fail in people. Most drugs that work in rodents fail in human trials, through lack of effect or unexpected harm. BPC-157’s healing effects have been shown almost entirely in rats and mice.
• Plausible mechanisms can cut both ways. BPC-157 promotes new blood vessel growth, which helps healing in animals. Researchers note that the same pathway is active in about half of studied human cancers, and no long-term human safety data exist.
• Purity is unknown. A private lab testing retatrutide from online vendors rated about 40% of the 179 vendors it lists as “poor”, “bad” or “fraud”. Some samples were impure or did not match their labelled strength.
• Harms are already being reported. In the first five months of 2026, the FDA received 26 adverse-event reports involving retatrutide, 11 of which needed hospital care.
• Anecdotes are not data. A clinic’s before-and-after photos cannot separate the peptide’s effect from rest, physiotherapy, diet or time.

The bottom line

If your goal is weight loss, the peptides with proven results are already approved and prescribed: semaglutide (Wegovy; Ozempic for diabetes) and tirzepatide (Mounjaro; Zepbound in the US), plus the older, less effective liraglutide (Saxenda). Setmelanotide (Imcivree) is approved only for rare genetic forms of obesity.

Two daily tablets are also licensed: the Wegovy pill (oral semaglutide), which is a peptide, and Foundayo (orforglipron), which acts on the same GLP-1 receptor but is a small molecule, not a peptide. In the UK they were licensed for weight management in June and August 2026, but neither is yet available on the NHS. Retatrutide may join them, but until it is approved, anything sold under that name is unregulated.

For the healing, longevity and performance peptides, the honest answer is that we do not yet know whether they work or are safe in people.

Before trying any peptide:

• Speak to a doctor or pharmacist, and tell them about anything you already take.
• Avoid products labelled “research use only” or “not for human consumption”.
• Use a registered pharmacy and a licensed product where one exists.
• Be wary of any seller whose evidence is testimonials or animal studies.

If you are in the UK:

• Check that any online pharmacy is registered with the General Pharmaceutical Council (or the PSNI in Northern Ireland).
• Expect a consultation before any prescription. A seller that skips it is not legitimate.
• Report side effects or suspected fakes through the MHRA Yellow Card scheme.

Useful next reads

• Who can get weight loss medication in the UK?
• Compare prices for Mounjaro, Wegovy, the Wegovy pill and Foundayo
• Browse the provider directory